Non-profit drug research and development: the case study of Genethon
Non-profit drug research and development (R&D) has the potential to deliver innovative treatments at affordable prices. Using the case study methodology, we discuss some ethical and economic issues, including the possible impact of non-profit companies on innovation efforts from for-profit firms...
Saved in:
| Main Authors: | Szymon Jarosławski, Mondher Toumi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-01-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20016689.2018.1545514 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Quantifying the persisting orphan-drug shortage public health crisis in the United States
by: Szymon Jarosławski, et al.
Published: (2017-01-01) -
A comparative study of orphan drug prices in Europe
by: Katherine Eve Young, et al.
Published: (2017-01-01) -
Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration
by: Szymon Jarosławski, et al.
Published: (2018-01-01) -
Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe
by: Goran Medic, et al.
Published: (2017-01-01) -
Are payers treating orphan drugs differently?
by: Joshua P. Cohen, et al.
Published: (2014-01-01)